Selective accumulation of virus-specific CD8+ T cells within the peripheral blood stem cell compartment
Open Access
- 27 August 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 114 (9), 2001-2003
- https://doi.org/10.1182/blood-2009-05-221267
Abstract
The absence of cellular immunity is central to the pathogenesis of herpesvirus-mediated diseases after allogeneic hemopoietic stem cell transplantation (HSCT). For both bone marrow (BM)– and granulocyte-colony stimulating factor–mobilized peripheral blood stem cells (PBSCs) HSCT, donor-derived Epstein-Barr virus (EBV) and cytomegalovirus (CMV) peptide–specific CD8+ T cells clones undergo early expansion and persist long-term, with additional diversification arising from novel antigen-specific clones from donor-derived progenitors. Whether BM or PBSC is the superior source of antiviral CD8+ T cells is unclear. Given that PBSC has largely replaced BM as a source of stem cells for HSCT, it is unlikely that herpesvirus effector T-cell reconstitution will ever be compared prospectively. PBSC grafts contain 10 to 30 times more T cells than BM and a randomized study found proven viral infections were more frequent in BM than PBSC recipients, suggesting viral-specific T-cell immunity is enhanced in PBSC. Recently Moss showed in lung cancer patients that herpesvirus-specific BM-derived CD8+ T cells have unique homing properties relative to herpesvirus-specific CD8+ T cells present in unmobilized peripheral blood (PB). Immunodominant EBV-lytic peptide–specific CD8+ T cells were enriched in BM but were reduced for CMV peptide–specific CD8+ T cells relative to PB. EBV-latent peptide–specific CD8+ T cells were equivalent, which has relevance in the context of posttransplantation lymphoproliferative disorder for which impaired EBV-latent CD8+ T-cell immunity is a risk-factor. A comparison of herpesvirus-specific cellular immunity in PBSC versus PB has yet to be performedKeywords
This publication has 8 references indexed in Scilit:
- Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrowBlood, 2008
- Moving targets: cell migration inhibitors as new anti-inflammatory therapiesNature Immunology, 2008
- Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr VirusAnnual Review of Immunology, 2007
- Epstein?Barr virus T-cell immunity despite rituximabBritish Journal of Haematology, 2007
- Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatmentsThe Lancet Infectious Diseases, 2004
- Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantationBlood, 2003
- Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantationBlood, 2001
- Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant RecipientsBlood, 1998